{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:29:45Z","timestamp":1773203385495,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.02.004","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:25:48Z","timestamp":1740039948000},"page":"e443-e451.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Melphalan 140 mg\/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9182-3931","authenticated-orcid":false,"given":"Jeries","family":"Kort","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3297-1041","authenticated-orcid":false,"given":"Nikolas","family":"Naleid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2968-4189","authenticated-orcid":false,"given":"Frank","family":"Oley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Ignatz-Hoover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5663-8319","authenticated-orcid":false,"given":"Seunghee","family":"Margevicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-5218","authenticated-orcid":false,"given":"Pingfu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Malek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9376-9377","authenticated-orcid":false,"given":"Brenda","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.clml.2025.02.004_bib0001","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.02.004_bib0002","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"New Eng J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.004_bib0003","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2022-159357","volume":"140","author":"Straka","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.02.004_bib0004","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2025.02.004_bib0005","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m2 or 200 mg\/m2 for autologous transplantation in myeloma: results from the Collaboration to collect autologous Transplant outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party","volume":"103","author":"Auner","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2025.02.004_bib0006","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.3324\/haematol.2021.279179","article-title":"Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma","volume":"106","author":"Srour","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2025.02.004_bib0007","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","article-title":"Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model","volume":"38","author":"Grazziutti","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2025.02.004_bib0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/bmt.2008.299","article-title":"The prospective oral mucositis audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT","volume":"43","author":"McCann","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2025.02.004_bib0009","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bmt.1705360","article-title":"High-dose melphalan (200 mg\/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol","volume":"37","author":"Jantunen","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.clml.2025.02.004_bib0010","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2025.02.004_bib0011","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2025.02.004_bib0012","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/14737159.2019.1627877","article-title":"ClonoSEQ assay for the detection of lymphoid malignancies","volume":"19","author":"Monter","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.clml.2025.02.004_bib0013","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk on JSTOR. Accessed December 17, 2024. https:\/\/www.jstor.org\/stable\/2241622"},{"issue":"446","key":"10.1016\/j.clml.2025.02.004_bib0014","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"7","key":"10.1016\/j.clml.2025.02.004_bib0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bmt.1705797","article-title":"Pharmacokinetics of melphalan in myeloma patients undergoing an autograft","volume":"40","author":"Nath","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2025.02.004_bib0016","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2125.2010.03638.x","article-title":"Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy","volume":"69","author":"Nath","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.clml.2025.02.004_bib0017","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/s41409-019-0628-8","article-title":"Pretransplant hemoglobin and creatinine clearance correlate with treatment-free survival after autologous stem cell transplantation for multiple myeloma","volume":"54","author":"Sweiss","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2025.02.004_bib0018","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bcp.12906","article-title":"High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation","author":"Nath","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.clml.2025.02.004_bib0019","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199310000-00005","article-title":"Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, bayesian fitting, and adaptive control","volume":"15","author":"Jelliffe","year":"1993","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.clml.2025.02.004_bib0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cpt.334","article-title":"Clinical decision support tools: the evolution of a revolution","volume":"99","author":"Mould","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.clml.2025.02.004_bib0021","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-13-1960","article-title":"Busulfan in infant to adult hematopoietic cell transplant recipients: A population pharmacokinetic model for initial and bayesian dose personalization","volume":"20","author":"McCune","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clml.2025.02.004_bib0022","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-017-0581-x","article-title":"Population pharmacokinetics and optimal sampling strategy for model-based precision dosing of Melphalan in patients undergoing hematopoietic stem cell transplantation","volume":"57","author":"Mizuno","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clml.2025.02.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.02.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","author":"Facon","year":"2024","journal-title":"New Eng J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T13:51:53Z","timestamp":1749477113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000680"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melphalan 140 mg\/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}